Answer
Yes, weight gain is a very common adverse reaction to Rozlytrek (entrectinib), reported in 34.1% of adult and paediatric clinical-trial patients, with grade 3 or higher weight gain in 10.6%.
Sources for this answer
- Rozlytrek 100 mg & 200 mg hard capsulesRoche Products Limited · emc · SmPC §4.8 Undesirable effects · Version 16Document updated
Sources checked